Novavax (NVAX) closed at $9.34 in the latest trading session, marking a +1.3% move from the prior day. The average of price targets set by Wall Street analysts indicates a potential upside of 81.6 ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced progress in Q4 2024 advancing its corporate growth strategy through ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

The average of price targets set by Wall Street analysts indicates a potential upside of 81.6% in Novavax (NVAX). While the effectiveness of this highly sought-after metric is questionable, the ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

The COVAIL trial reveals that neutralizing antibody titers correlate with COVID-19 risk reduction after mRNA boosters. Learn how this impacts vaccine strategies against emerging variants.

A clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, only slightly lower than the 96% efficacy seen with the original strain of the ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Can you hear me now? If your callers say that you're cutting in and out, it actually might ...

Inovio Pharmaceuticals Inc. 0.00% $75.45M ...